Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527026) titled 'A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer' on April 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chinese PLA General Hospital
Condition:
Locally Advanced Rectal Cancer
Intervention:
Drug: Camrelizumab
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 1, 2026
Target Sample Size: 44
Countries of Recruitment:
Chi...